Diclofenac sodium in the treatment of osteoarthritis

Aging Health

Volumn 2, Issue 2, 2006, Pages 179-187

  Rohekar, Gina ^a   Bookman, Arthur A M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diclofenac; Gastric ulceration; Nonsteroidal anti inflammatory drugs; Osteoarthritis; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CODEINE; CYCLOOXYGENASE 2; CYCLOSPORIN; DICLOFENAC; DICLOFENAC POTASSIUM; DIFLUNISAL; DIGOXIN; FLURBIPROFEN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IBUPROFEN; INDOMETACIN; LITHIUM; MEFENAMIC ACID; METHOTREXATE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYLACETIC ACID DERIVATIVE; PIROXICAM; PLACEBO; PREDNISONE; SALICYLIC ACID; SULINDAC; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

ANTIINFLAMMATORY ACTIVITY; APPETITE DISORDER; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EDEMA; EXCITEMENT; FIRST PASS EFFECT; GASTROINTESTINAL TOXICITY; HEADACHE; HEARING DISORDER; HEART INFARCTION; HEMATEMESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; LIVER DYSFUNCTION; META ANALYSIS; NAUSEA AND VOMITING; OSTEOARTHRITIS; PEPTIC ULCER; PHARMACODYNAMICS; SIDE EFFECT; SLOW RELEASE FORMULATION; STOMACH DISCOMFORT; SUPPOSITORY; SYSTEMATIC REVIEW; TABLET FORMULATION; THROMBOSIS; VISUAL DISORDER;

EID: 33646570520     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.2.2.179     Document Type: Article

References (54)

1. Maddison PJ, Isenberg DA, Woo P, Glass DN, Breedveld F: Oxford Textbook of Rheumatology (2nd Edition). Oxford University Press, Oxford, UK (1993).
2. Primer on the Rheumatic Diseases (12th Edition). Klippel JH (Ed.) The Arthritis Foundation, Atlanta, GA, USA (2001).
3. Tugwell PS, Wells GA, Shainhouse JZ: Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J. Rheumatol. 31(10). 2002-2012 (2004).
4. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Guidelines. Arthritis Rheum. 43(9). 1905-1915 (2000).
5. Hawkey CJ: NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective. Clin. Exp. Rheumatol. 19(6 Suppl. 25), S23-S30 (2001).
6. Bresalier RS, Sandler RS, Quan H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352(11), 1092-1102 (2005).
7. Small RE: Diclofenac sodium. Clin. Pharm. 8(8), 545-558 (1989).
8. Mosby's Drug Consultant (15th Edition). Mosby Inc., St. Louis, MO, USA (2005).
9. Davies NM, Anderson KE: Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin. Pharmacokinet. 33(3), 184-213 (1997).
10. FitzGerald GA, Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345(6), 433-442 (2001).
11. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364(9450). 2021-2029 (2004).
12. Cryer B. Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 104(5), 413-421 (1998).
13. Silverstein F, Faich G, Goldstein J et al.: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis, the CLASS Study: a randomized controlled trial. JAAM 284, 1247-1255 (2000).
14. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case - control analysis. Br. Med. J. 330(7504), 1366 (2005).
15. Riess W, Stierlin H, Degen P et al.: Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. Scand. J. Rheumatol. Suppl. 22, 17-29 (1978).
16. Small RE: Diclofenac, sodium. Clin. Pharm. 8(8), 545-558 (1989).
17. Todd PA, Sorkin EM: Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 35(3), 244-285 (1988).
18. Catella-Lawson F, Reilly MP, Kapoor SC et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345(25), 1809-1817 (2001).
19. Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS: Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs 20(1), 24-48 (1980).
20. Skoutakis VA, Carter CA, Mickle TR et al.: Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intell. Clin. Pharm. 22(11), 850-859 (1988).
21. Altman R: International experiences with diclofenac in osteoarthritis. Am. J. Med. 80(4B), 48-52 (1986).
22. Ward JR: Efficacy of diclofenac in osteoarthritis. Experience in the United States. Am. J. Med. 80(4B), 53-57 (1986).
23. Wietfed K, Rubsamen B, Rechziegler H, Bernard I: Therapie mitt acemetacin und diclofenac bei patienten mit degenerativen gelenkerkrankungen. Med. Welt 37, 1073-1076 (1986).
24. Willkens RF: Worldwide clinical safety experience with diclofenac. Semin. Arthritis Rheum. 15(2 Suppl. 1), 105-110 (1985).
25. Catalano MA: Worldwide safety experience with diclofenac. Am. J. Med. 80(4B), 81-87 (1986).
26. Niccoli L, Bellino S, Cantini F: Renal tolerability of three commonly employed non-steroidal anti-inflammatory drugs in elderly patients with osteoarthritis. Clin. Exp. Rheumatol. 20(2), 201-207 (2002).
27. Hasan M, Otoom S, Najib N, Sallam el-S: A two-way cross-over bioequivalence study comparing two products of diclofenac sodium suppositories in healthy human volunteers. Basic Clin. Pharmacol. Toxicol. 95(6), 263-265 (2004).
28. Pavelka K, Susta A, Kankova D, Vojtisek O: Comparison of three therapeutic regimens using nonsteroidal antirheumatic drugs in patients with rheumatoid arthritis. Z. Rheumatol. 40(4), 165-170 (1981).
29. Wafin F, Valindas E, Wuolijoki E: Comparison of diclofenac and indomethacin suppositories in rheumatoid arthritis. Clin. Rheumatol. 3(1), 67-70 (1984).
30. Karim A, Smith M: Biopharmaceutical profile of diclofenac - misoprostol combination tablet, Arthrotec. Scand. J. Rheumatol. Suppl. 96, 37-48 (1992).
31. Doherty M: The efficacy of Arthrotec in the treatment of osteoarthritis. Scand. J. Rheumatol. Suppl. 96, 15-21 (1992).
32. Gagnier P: Review of the safety of diclofenac/misoprostol. Drugs 45(Suppl. 1), 31-35 (1993).
33. Downie WW: Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis. Drugs 45(Suppl. 1), 1-6; discussion 36-37 (1993).
34. Karim A: Pharmacokinetics of diclofenac and misoprostol when administered alone or as a combination product. Drugs 45(Suppl. 1), 7-13; discussion 14 (1993).
35. Pincus T, Koch GG, Sokka T et al.: A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum. 44(7), 1587-1598 (2001).
36. Morgan D: Arthrotec: the evidence speaks for itself. Scand. J. Rheumatol. Suppl. 109, 13-18 (1999).
37. Hui X, Hewitt PG, Poblete N. Maibach HI, Shainhouse JZ, Wester RC: In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm. Res. 15(10), 1589-1595 (1998).
38. Bookman AA, Williams KS, Shainhouse JZ: Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 171(4), 333-338 (2004).
39. Roth SH, Shainhouse JZ: Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch. Intern. Med. 164(18), 2017-2023 (2004).
40. Ciccolunghi SN, Levi B, Chaudri HA: Clinical experience with Voltaren, a new nonsteroidal anti-rheumatic drug. Therapiewoche 26, 2908-2914 (1996).
41. Stegink AJ: Diclofenac Na (Voltaren) in the treatment of osteoarthritis of the spine: a long-term (six months) comparative trial versus indomethacin. Tgo Tijdschrijft Voor Geneesmiddelenonderzoek 5, 41-55 (1977).
42. Alegre Marcet C, Barcelo Torrent P, Casademont Vilaseca M, de Dalmases Gose R, Castano B: Double-blind multicentric, comparative between-patient trial of diclofenac and indomethacin, in arthritis treated during 3 months. Clinical and biological evaluation and statistic analysis of the results. Rev. Esp. Reum. Enferm. Osteoartic. 20(2), 139-137 (1977).
43. Joubert PT, Kushlik AR, McNeill WG, Sheard ES, Muller FO: South African multicentre trial with Voltaren in asteoarthritis of the knee. S. Afr. Med. J. 48, 1973-1978 (1974).
44. Chavarria C, Castresano-Isla C: Diclofenac sodium versus acetylsalicyclic acid in the treatment of osteoarthritis. Trib. Med. 14, 77-82 (1976).
45. Torralba TP: A short-term between-patient comparison of diclofenac sodium and acetysalicyclic acid in osteoarthritis of the knee and hip. Phillipp. J. Intern. Med. 14, 77-82 (1976).
46. Bach GL: Comparative clinical trials with diclofenac sodium (Voltarol) and naproxen in rheumatic conditions: investigation of possible changes in diclofenac dose and dose interval. Rheumatol. Rehabil. Suppl. 2, 69-74 (1979).
47. Car A, Jajic I, Krampac I, Vitaus M, Zenic N, Zivkovic M: A double-blind multi-centre comparison of diclofenac sodium and naproxen in osteoarthritis of the hip. Scand. J. Rheumatol. Suppl. 22, 63-68 (1978).
48. Siegmeth W, Placheta P: Long-term comparative study: diclofenac (voltaren) and naproxen (proxen) in arthritis. Schweiz. Med. Wochenschr. 108(9), 349-353 (1978).
49. Scharf Y, Nahir M, Schapira D. Lorber M: A comparative study of naproxen with diclofenac sodium in osteoarthrosis of the knees. Rheumatol. Rehabil. 21(3), 167-170 (1982).
50. Coimbra F: Report from the general out-patient hospital, Rheumatological Hospital, Rio de Janeiro. National experience with diclofenac sodium. Round table, Ninth Brazilian Congress on Rheumatology, Forhale. Bras Reum, Fortaleza, Brazil, 27-33 (1977).
51. Rossi FA, Balladore GB, Baroni L: A short-term comparison between diclofenac sodium (D) and sulindac (S) in osteoarthritis of the elderly. Proceedings of the Ninth European Congress on Rheumatology. Wiesbaden, Germany, September 2-8, 176 (1979).
52. Garcia Rodriguez LA, Gonzalez-Perez A: Long term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med. 3, 17 (2005).
53. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmöller J: Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br. J. Clin. Pharmacol. 55(1), 51-61 (2003).
54. Cheng HF, Wang SW, Zhang MZ, McKanna JA, Breyer R, Harris RC: Prostaglandins that increase renin production in response to ACE inhibition are not derived from cyclooxygenase-1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283(3), R638-R646 (2002).